BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced that it has entered into a peptide purchase agreement with Peptisyntha, Inc., a peptide manufacturer. The agreement includes a commitment by Helix to purchase peptides over an eighteen-month period for total consideration of $234,000. In addition, Helix recently completed a smaller purchase of peptides from the same supplier for total consideration of $64,000.
